Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Orphazyme A/S
  6. News
  7. Summary
    ORPHA   DK0060910917

ORPHAZYME A/S

(ORPHA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Higher in Monday Trading

06/14/2021 | 11:22am EDT


ę MT Newswires 2021
All news about ORPHAZYME A/S
07/22European ADRs Modestly Lower Thursday as Unilever Slides
MT
07/21DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
BU
07/20GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Class..
BU
07/19ORPH SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Orphazyme A/..
BU
07/19CytRx Corporation Announces Closing of $10 Million Offering To Healthcare-Foc..
AQ
07/17EQUITY ALERT : ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Orphazyme A/S Investor..
BU
07/17THE LAW OFFICES OF FRANK R. CRUZ : Announces the Filing of a Securities Class Ac..
BU
07/16GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces the..
BU
07/16INVESTOR ALERT : Law Offices of Howard G. Smith Announces the Filing of a Securi..
BU
07/16SHAREHOLDER ALERT : Robbins LLP Announces that Orphazyme A/S (ORPH) is Being Sue..
BU
More news
Financials
Sales 2021 32,2 M 5,12 M 5,12 M
Net income 2021 -520 M -82,6 M -82,6 M
Net cash 2021 47,9 M 7,60 M 7,60 M
P/E ratio 2021 -2,66x
Yield 2021 -
Capitalization 1 181 M 187 M 188 M
EV / Sales 2021 35,1x
EV / Sales 2022 5,81x
Nbr of Employees 141
Free-Float 98,6%
Chart ORPHAZYME A/S
Duration : Period :
Orphazyme A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORPHAZYME A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 33,78 DKK
Average target price 81,00 DKK
Spread / Average Target 140%
EPS Revisions
Managers and Directors
Christophe Bourdon Chief Executive Officer
Anders Fink Vadsholt Chief Financial Officer
Georges Gemayel Chairman
Thomas Kirkegaard Jensen Chief Scientific Officer
Claus BornŠs Senior Manager-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ORPHAZYME A/S-49.69%261
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.32.49%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308